Jing Chen
Merck & Co.
7 Papers
128 Citations
Jing Chen is an academic researcher from Merck & Co.. The author has contributed to research in topics: Inverse agonist & Nicotinic agonist. The author has an hindex of 6, co-authored 7 publications.
Chat about Author
Papers
Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists.
Christopher W. Plummer,Paul E. Finke,Sander G. Mills,Junying Wang,Xinchun Tong,George A. Doss,Tung M. Fong,Julie Z. Lao,Marie-Therese Schaeffer,Jing Chen,Chun-Pyn Shen,D. Sloan Stribling,Lauren P. Shearman,Alison M. Strack,Lex H.T. Van der Ploeg +14 more
TL;DR: The two amide derivatives 24a and b (hCB1 IC50 = 6.1 and 4.0 nM) demonstrated efficacy in overnight feeding studies in the rat for reduction in both food intake and overall body weight.
62
Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists.
Laura C. Meurer,Paul E. Finke,Sander G. Mills,Thomas F. Walsh,Richard B. Toupence,Mark T. Goulet,Junying Wang,Xinchun Tong,Tung M. Fong,Julie Lao,Marie-Therese Schaeffer,Jing Chen,Chun-Pyn Shen,D. Sloan Stribling,Lauren P. Shearman,Alison M. Strack,Lex H.T. Van der Ploeg +16 more
TL;DR: The synthesis and biological activities of the 2-benzyloxy-5-(4-chlorophenyl)-6-(2,4-dichlorophenyl)pyridines having either a 3-cyano or 3-carboxamide moiety as potent and selective hCB1 inverse agonists are described.
35
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.
Helen E. Armstrong,Amy Galka,Linus S. Lin,Thomas J. Lanza,James P. Jewell,Shrenik K. Shah,Guthikonda Ravi N,Quang Truong,Linda L. Chang,Grace M. Quaker,Vincent J. Colandrea,Xinchun Tong,Junying Wang,Sherry Xu,Tung M. Fong,Chun-Pyn Shen,Julie Lao,Jing Chen,Lauren P. Shearman,D. Sloan Stribling,Kimberly Rosko,Alison M. Strack,Sookhee Ha,Lex H.T. Van der Ploeg,Mark T. Goulet,William K. Hagmann +25 more
TL;DR: Sulfonamide analogues of the potent CB1R inverse agonist taranabant were prepared and optimized for potency and selectivity forCB1R, and the most potent representative had good pharmacokinetic and brain levels, but was modestly active in blocking CB1r agonist-mediated hypothermia.
20
Discovery of a Potent and Selective ROMK Inhibitor with Pharmacokinetic Properties Suitable for Preclinical Evaluation.
Shawn P. Walsh,Aurash Shahripour,Haifeng Tang,Nardos Teumelsan,Jessica Frie,Yuping Zhu,Birgit T. Priest,Andrew M. Swensen,Jessica Liu,Michael Margulis,Richard Visconti,Adam B. Weinglass,John P. Felix,Richard M. Brochu,Timothy Bailey,Brande Thomas-Fowlkes,Magdalena Alonso-Galicia,Xiaoyan Zhou,Lee-Yuh Pai,Aaron Corona,Caryn Hampton,Melba Hernandez,Ross Bentley,Jing Chen,Kashmira Shah,Joseph M. Metzger,Michael J. Forrest,Karen Owens,Vincent Tong,Sookhee Ha,Sophie Roy,Gregory J. Kaczorowski,Lihu Yang,Emma R. Parmee,Maria L. Garcia,Kathleen A. Sullivan,Alexander Pasternak +36 more
TL;DR: The excellent selectivity for ROMK inhibition over related ion channels and pharmacokinetic properties across preclinical species support further preclinical evaluation of 28 as a new mechanism diuretic.
CorrigendumCorrigendum to “Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists”: [Bioorg. Med. Chem. Lett. 15 (2005) 645]
Laura C. Meurer,Paul E. Finke,Sander G. Mills,Thomas F. Walsh,Richard B. Toupence,John S. Debenham,Mark T. Goulet,Junying Wang,Xinchun Tong,Tung M. Fong,Julie Lao,Marie-Therese Schaeffer,Jing Chen,Chun-Pyn Shen,D. Sloan Stribling,Lauren P. Shearman,Alison M. Strack,Lex H.T. Van der Ploeg +17 more
TL;DR: Meurer et al. as discussed by the authors proposed an approach for the treatment of metabolic disorders at Merck Research Laboratories, which is a division of the Merck Institute of Metabolism.
3